Heart metastatic malignant melanoma is the late stage of tumor development.Treatment is mainly to alleviate symptoms and support the treatment of the whole body, such as anemia, edema, hypoproteinemia.For pleural or pericardial effusion should be punctured as soon as possible or catheter drainage, in order to reduce the cardiopulmonary compression.Chemotherapy and immunotherapy can be used in patients with better systemic status, but malignant melanoma is not sensitive to the former, while the latter has a certain effect on enhancing the patient's immunity.Radiotherapy can be used as an experimental therapy and can also confirm the presence or absence of cardiac metastasis.Arrhythmias are sometimes controlled by digitalis therapy.
This report contains market size and forecasts of Metastatic Malignant Melanoma Therapy in Global, including the following market information:
Global Metastatic Malignant Melanoma Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Metastatic Malignant Melanoma Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Immunotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metastatic Malignant Melanoma Therapy include Merck, Pfizer, Janssen Biotech, Roche, Navidea, Novartis, Bristol-Myers Squibb, Enzon Pharmaceuticals and Exelixis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Malignant Melanoma Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Malignant Melanoma Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Malignant Melanoma Therapy Market Segment Percentages, by Type, 2021 (%)
Immunotherapy
Targeted Therapy
Other
Global Metastatic Malignant Melanoma Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Malignant Melanoma Therapy Market Segment Percentages, by Application, 2021 (%)
Hospital
Medical Research Organization
Other
Global Metastatic Malignant Melanoma Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Metastatic Malignant Melanoma Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Malignant Melanoma Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Metastatic Malignant Melanoma Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Pfizer
Janssen Biotech
Roche
Navidea
Novartis
Bristol-Myers Squibb
Enzon Pharmaceuticals
Exelixis
GlaxoSmithKline
Ono Pharmaceutical
Amgen